Investigating skin blistering caused by toxic substances

Dermal-Epidermal Junction Disruptors: Toxicodynamic Mechanisms

NIH-funded research St. John's University · NIH-10885002

This study is looking at how certain harmful substances can cause skin blisters and aims to find out how the immune system and skin proteins are involved, with hopes of discovering better ways to treat skin injuries for people affected by these toxins.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionSt. John's University NIH-funded
Lab location1 site (Queens, United States)
Project IDNIH-10885002 on NIH RePORTER

What this research studies

This research focuses on understanding how certain toxic substances, known as dermal-epidermal junction (DEJ) disruptors, cause the skin to blister. The study will examine the role of various immune mediators and skin proteins in this process using mouse models. By applying different treatments before exposing the skin to these toxic agents, researchers aim to uncover the mechanisms behind skin damage and potential ways to mitigate it. The findings could lead to better treatments for skin injuries caused by these disruptors.

Who could benefit from this research

Good fit: Ideal candidates for this research would include individuals with conditions that cause skin blistering or those exposed to toxic substances affecting the skin.

Not a fit: Patients with skin conditions unrelated to DEJ disruption or those not exposed to relevant toxic agents may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved treatments for skin blistering and better understanding of skin injury mechanisms.

How similar studies have performed: While the specific mechanisms of DEJ disruption are not well-studied, related research on skin injury and immune response has shown promising results.

Where this research is happening

Queens, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer Agents
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.